Collectively, these findings revealed that the antitumor efficacy of HM-3/HSA was higher than that of HM-3 in vivo and when HSA was fused at the C-terminus of HM-3, the anti-tumor activity was better than when fused at the N-terminus. Here, CHRM3 is linked to neoplasm.